AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Market Closed 02-20 16:00:00 EST

3.04

-0.18

-5.59%

盘后2.99

-0.05-1.56%

19:51 EST

High3.18	Low2.97	Vol4.70M
Open3.16	D1 Closing3.22	Amplitude6.68%
Mkt Cap909.98M	Tradable Cap616.36M	Total Shares299.34M
T/O14.31M	T/O Rate2.32%	Tradable Shares202.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":3.04,"timestamp":1771621200000,"preClose":3.22,"halted":0,"volume":4702434,"hourTrading":{"tag":"盘后","latestPrice":2.9925,"preClose":3.04,"latestTime":"19:51 EST","volume":38968,"amount":118520.4336,"timestamp":1771635102837,"change":-0.0475,"changeRate":-0.015625,"amplitude":0.028783},"delay":0,"changeRate":-0.055900621118012465,"floatShares":202749853,"shares":299335048,"eps":-0.576766,"marketStatus":"Market Closed","change":-0.18,"latestTime":"02-20 16:00:00 EST","open":3.16,"high":3.18,"low":2.965,"amount":14310187.1041998,"amplitude":0.06677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.576766,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":3.22,"preHourTrading":{"tag":"盘前","latestPrice":3.15,"preClose":3.22,"latestTime":"09:29 EST","volume":23639,"amount":76368.62618,"timestamp":1771597770030,"change":-0.07,"changeRate":-0.021739,"amplitude":0.037267},"postHourTrading":{"tag":"盘后","latestPrice":2.9925,"preClose":3.04,"latestTime":"19:51 EST","volume":38968,"amount":118520.4336,"timestamp":1771635102837,"change":-0.0475,"changeRate":-0.015625,"amplitude":0.028783},"volumeRatio":1.7931404021670576,"impliedVol":1.0671,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"2610668439","title":"AbCellera Biologics to Present at Major Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610668439","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610668439?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:06","pubTimestamp":1770844003,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc.  will participate in several upcoming investor conferences in March and April 2026. The company is scheduled to present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026, the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, and the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026. Live audio webcasts of each presentation will be accessible through a link posted on AbCellera's Investor Relations website closer to the date, with replays available through the same link following the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on February 11","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLb0q3Qm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2610666389","title":"11 Stocks That Have Cratered and Look Like Buys -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610666389?lang=en_us&edition=fundamental","pubTime":"2026-02-10 03:22","pubTimestamp":1770664920,"startTime":"0","endTime":"0","summary":"Sometimes, an opportunity to buy something is hiding in plain sight. That is a distinct possibility today, considering the tons of stocks that have crashed recently.Enormous drops in stocks have historically provided some of the best buying opportunities. When a concern emerges, prices fall to levels that fully reflect the worry, whether the risk that caused the selloff materializes or not. That sets the shares up to benefit from any improvement in sentiment.Elsewhere, companies that provide private loans and equity financing, via private investment funds, have seen their stocks tank. Even shares of the investment bank Jefferies, which owns a stake in a hedge fund that had exposure to private credit, are down 14% from a multimonth high hit in September. To make the list, short interest had to be in the 65th percentile of the historic range for each company, or higher, meaning that the st","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","LU0648001328.SGD","LU0107464264.USD","LU0545039389.USD","LU0353189680.USD","LU0882574055.USD","SDGR","LU2461242641.AUD","LU2264538146.SGD","LU1934455863.HKD","IE00B4JS1V06.HKD","LU2087625088.SGD","BK4527","LU1633808545.USD","LU0316494557.USD","LU0069063385.USD","SG9999017495.SGD","IE00BZ1G4Q59.USD","LU0158827781.USD","LU0234570918.USD","LU0557290698.USD","LU2125154778.USD","LU1506573853.SGD","BK4607","LU0158827948.USD","LU0130517989.USD","IE00B19Z8W00.USD","LU1923622614.USD","IE0002270589.USD","IE00BWXC8680.SGD","BK4608","LU0496365809.HKD","IE00B4R5TH58.HKD","LU1551013342.USD","LU0114720955.EUR","LU2063271972.USD","LU2125909247.SGD","SG9999014914.USD","LU0354030511.USD","LU1778281490.HKD","BK4538","LU0314104364.USD","LU2125909759.SGD","LU2106854487.HKD","ADBE","LU0719512351.SGD","IE000M9KFDE8.USD","LU2242649171.HKD","LU0211328371.USD","IE00BZ9MQY76.HKD","LU1116320737.USD","LU1267930227.SGD","OWL","LU0061474960.USD","SG9999013999.USD","LU0949170772.SGD","LU0965509283.SGD","LU1003077747.HKD","BK4503","LU1983299246.USD","LU1066051225.USD","SG9999014898.SGD","LU0345770993.USD","LU0672654240.SGD","LU0052756011.USD","LU0742534661.SGD","BK4598","LU0708995401.HKD","LU1670628061.USD","SG9999014906.USD","LU0310800379.SGD","BK4505","LU0823416689.USD","LU0689472784.USD","SAIL","BK4550","LU0266013472.USD","IE00B7SZLL34.SGD","LU0310799852.SGD","BK4097","LU1084165304.USD","LU1814569148.SGD","LU0289739343.SGD","IE00BN29S564.USD","LU1815333072.USD","SG9999001176.SGD","BK4579","BK4532","LU1791710400.SGD","IE00B1XK9C88.USD","LU0823434740.USD","LU1201861249.SGD","WDAY","LU0320765059.SGD","IE00BFSS8Q28.SGD","LU0889565833.HKD","LU0127658192.USD","LU0861579265.USD","LU1718418525.SGD","LU2133065610.SGD","LU0094547139.USD","LU2211815571.USD","LU0211326755.USD","LU1923623000.USD","LU2468319806.SGD","LU1914381329.SGD","LU2236285917.USD","LU0203347892.USD","LU0354030438.USD","LU0661504455.SGD","IE00BJJMRY28.SGD","LU1066051811.HKD","LU2491050154.USD","LU0006306889.USD","LU2111349929.HKD","LU0029864427.USD","LU2095319765.USD","BK4566","LU1989772840.SGD","LU0048573561.USD","BK4548","LU0251132253.USD","LU1119994496.HKD","LU2756315664.SGD","UNHW","LU2125909916.SGD","LU0868494617.USD","LU0823434583.USD","LU2237438978.USD","IE00B7KXQ091.USD","LU1720051017.SGD","LU0943347566.SGD","SGXZ99366536.SGD","BK4588","LU0417517546.SGD","IE00B5TLWC47.USD","LU0251142724.SGD","LU1064131342.USD","LU2023250843.SGD","LU1854104046.USD","LU0980610538.SGD","BK4533","LU2543165471.USD","LU0289739699.SGD","LU0211326839.USD","LU1291159041.SGD","LU0234572021.USD","LU1674673428.USD","LU0109392836.USD","IE00B19Z3B42.SGD","IE0004445239.USD","LU0553294199.USD","UNHG","LU2552382058.USD","IE00BJTD4N35.SGD","LU2210149790.SGD","LU0511384066.AUD","LU0456855351.SGD","LU1267930730.SGD","LU0942090050.USD","LU0265550946.USD","LU0345770308.USD","LU2361044865.SGD","LU1823568750.SGD","LU2552382132.HKD","IE00BFTCPJ56.SGD","LU0170899867.USD","LU1057294990.SGD","LU1316542783.SGD","IE00B19Z3581.USD","LU2271345857.HKD","LU2360032135.SGD","LU2361044949.HKD","LU0868494708.USD","LU0795875169.SGD","LU0203345920.USD","LU0238689110.USD","BK4592","SG9999002232.USD","LU0965509101.SGD","LU0011850046.USD","IE00B19Z9Z06.USD","LU0128525689.USD","LU1732800096.USD","IE00BJTD4V19.USD","LU0058720904.USD","LU1854103824.USD","ABSI","LU1069347547.HKD","LU0477156953.USD","LU0082616367.USD","LU0708994859.HKD","IE00BQXX3D17.EUR","LU2286300806.USD","LU0124676726.USD","LU1267930573.SGD","LU2362540622.SGD","LU0795875086.SGD","IE0009356076.USD","LU2347655156.SGD","LU0528227936.USD","IE00BQXX3F31.USD","LU0345774391.USD","BK4585","LU1670627923.USD","LU2023251221.USD","LU2361045086.USD","LU0097036916.USD","LU2244417387.USD","LU1323610961.USD","SG9999018857.SGD","LU1551013425.SGD","LU1623119135.USD","LU0957791311.USD","LU0267386448.USD","LU1974910355.USD","SGXZ31699556.SGD","BK4567","BK4561","LU0048584097.USD","LU2089283258.USD","IE00BFSS7M15.SGD","LU0106261372.USD","SGXZ51526630.SGD","IE00BFXG1179.USD","LU0265550359.USD","IE0004445015.USD","IE00BMPRXR70.SGD","LU0348723411.USD","LU1046421795.USD","LU1674673691.USD","IE00BJJMRZ35.SGD","LU0057025933.USD","SG9999014880.SGD","IE00BQXX3C00.GBP","LU0912757837.SGD","LU2210150020.SGD","IE00B19Z9505.USD","LU2112291526.USD","SG9999001424.SGD","CRM","LU0820561909.HKD","LU2028103732.USD","LU0353189763.USD","LU1691799644.USD","LU1267930490.SGD","LU0787776722.HKD","LU1989772923.USD","ABCL","LU0053666078.USD","LU1989764664.SGD","BK4023","LU1988902786.USD","BK4543","LU2552382215.SGD","IE00BMPRXN33.USD","LU2362541273.HKD","LU1116320901.HKD","IE00B1BXHZ80.USD","LU0342679015.USD","IE00BKPKM429.USD","BK4528","LU2357305700.SGD","LU0472753341.HKD","LU1074936037.SGD","IE00BJT1NW94.SGD","LU1267930813.SGD","LU0211327993.USD","BK4534","BK4554","IE00B775H168.HKD","LU0157215616.USD","LU0077335932.USD","IE00BJJMRX11.SGD","LU2089984988.USD","SG9999018865.SGD","LU2381873111.SGD","NOW","LU0130102774.USD","LU2491049909.HKD","BK4535","LU1235294995.USD","LU1732799900.SGD","LU2362541513.USD","LU0976567544.SGD","LU2125909593.SGD","LU0642271901.SGD","LU0820561818.USD","LU1061106388.HKD","LU2265009873.SGD","LU1791710582.SGD","IE00BYQQ9H92.USD","UNH","LU1066051498.USD","IE0005OL40V9.USD","IE00B894F039.SGD","LU1035773651.USD","LU1037948897.HKD","LU2756315318.SGD","SG9999000418.SGD","LU1934455277.USD","LU0689626769.HKD","LU0109391861.USD","BK4154","LU1923622291.USD","LU1261432733.SGD","LU1496350171.SGD","IE00BKVL7J92.USD","RXRX","LU1548497426.USD","LU1989764748.USD","LU2125154935.USD","IE00B19Z8X17.USD","LU2491050071.SGD","SG9999002224.SGD","LU1951198990.SGD","LU0251131958.USD","LU0198837287.USD","LU0820562030.AUD","LU1951200564.SGD","LU1066053197.SGD","BK4613","LU2324357040.USD","IE00B2B36J28.USD","LU1153585028.USD","LU2458330243.SGD","LU1804176565.USD","IE0002141913.USD","LU1496350502.SGD","LU0965509010.AUD","LU0149725797.USD","LU1023059063.AUD","IE0009355771.USD","LU2279689827.SGD","LU0079474960.USD","SGXZ81514606.USD","LU0122379950.USD","LU2458330169.SGD","LU0432979614.USD","LU0738911758.USD","LU0792757196.USD","LU1366333091.USD","LU2089284900.SGD","LU0889566641.SGD","LU0187121727.USD","LU1934455194.USD","LU2023250504.SGD","LU0256863811.USD","LU1720051108.HKD","LU0310800965.SGD","LU1803068979.SGD","IE00BFXG0V08.USD","LU2317271919.USD","LU2247934214.USD","LU0289961442.SGD","LU0081259029.USD","LU2433249047.HKD","LU1037948541.HKD","LU1917777945.USD","LU1989771016.USD","LU1712237335.SGD","SGXZ57979304.SGD","SG9999001176.USD","BK4581","IE00B19Z9P08.USD","LU0965508806.USD","LU0128525929.USD","IE00BSNM7G36.USD","LU0345774631.USD"],"gpt_icon":0},{"id":"2607604810","title":"AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2607604810","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607604810?lang=en_us&edition=fundamental","pubTime":"2026-01-30 16:38","pubTimestamp":1769762283,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635.\nABCL635 is a non hormonal candidate for treating moderate to severe vasomotor symptoms associated with menopause.\nThis Phase 2 dosing milestone marks further clinical progress in the company's efforts to develop a potential first in class menopause therapy.\n\nAbCellera Biologics, known for its antibody discovery platform, is pushing deeper into clinical development...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2605446662","title":"Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605446662","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605446662?lang=en_us&edition=fundamental","pubTime":"2026-01-23 08:10","pubTimestamp":1769127000,"startTime":"0","endTime":"0","summary":"AbCellera  will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time  the same day.A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.AbCellera  is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2605055412","title":"Abcellera Biologics Inc. to Announce Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2605055412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605055412?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:05","pubTimestamp":1769115945,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. will announce its full year 2025 financial results on Tuesday, February 24, 2026. The company will hold an earnings conference call at 2:00 p.m. Pacific Time  the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL1Pj5kY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2603476406","title":"AbCellera Biologics Showcases Progress in Antibody Drug Development and Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2603476406","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603476406?lang=en_us&edition=fundamental","pubTime":"2026-01-15 06:04","pubTimestamp":1768428291,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. has provided an update on its pipeline and recent developments. The company reported advancement of its internal programs, with two molecules—ABCL635 and ABCL575—now in clinical trials. ABCL635, targeting NK3R, is in a Phase 1/2 trial focused on endocrinology and women's health, while ABCL575, targeting OX40L, is in a Phase 1 trial for immunology and inflammation. Two additional candidates, ABCL688 and ABCL386, are progressing through IND-enabling studies in the areas of autoimmunity and oncology, respectively. The company has also initiated activities at its new clinical manufacturing facility and maintains over $680 million in available liquidity. AbCellera plans to nominate at least one more development candidate for IND-enabling studies in the coming year. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL6FV8lG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2603544936","title":"AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2603544936","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603544936?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:58","pubTimestamp":1768233502,"startTime":"0","endTime":"0","summary":"AbCellera Biologics  said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.Shares of AbCellera Biologics were up 1.5% in recent trading.Price: 4.44, Change: +0.06, Percent Change: +1.49","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2602054612","title":"AbCellera doses first patients in Phase 2 portion of ABCL635 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054612","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602054612?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:36","pubTimestamp":1768228583,"startTime":"0","endTime":"0","summary":"AbCellera (ABCL) announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a po...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-doses-first-patients-in-phase-2-portion-of-abcl635-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-doses-first-patients-in-phase-2-portion-of-abcl635-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2602854530","title":"BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2602854530","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602854530?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:11","pubTimestamp":1768227091,"startTime":"0","endTime":"0","summary":"BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug** Shares of drugmaker AbCellera ABCL.O rise 6.2% to $4.64 in premarket trading** Co says it has started dosing patients in a mid-stage trial for ABCL635, its experimental drug aimed at treating hot flashes and other moderate-to-severe symptoms linked to menopause** Drug aims to ease hot flashes and other moderate-to-severe menopause symptoms, per co** Co's ABCL635 offers non-hormonal alternative for women avoiding hormone therapy** Trial will enroll 80 postmenopausal women; results expected in Q3 2026 - ABCL** As of last close, stock up ~17% over the past year  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2602754543","title":"AbCellera Begins Phase 2 Trial of ABCL635 for Menopausal Vasomotor Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754543","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602754543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:01","pubTimestamp":1768226505,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. has announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause. The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial that will evaluate the efficacy of ABCL635 in reducing the frequency and severity of vasomotor symptoms in 80 postmenopausal women. The transition to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from the Phase 1 portion of the study. Top-line clinical results for both phases are expected to be presented in the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL53FvFn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2602543479","title":"Abcellera Announces First Patients Dosed in Phase 2 Portion of Its Phase 1/2 Clinical Trial of Abcl635 for the Treatment of Vasomotor Symptoms Due to Menopause","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543479?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226407,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7R2PZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2602543421","title":"Abcellera Biologics Inc - Anticipates Top-Line Results in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543421?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226407,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7R2PZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2592194443","title":"AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194443","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194443?lang=en_us&edition=fundamental","pubTime":"2025-12-20 03:36","pubTimestamp":1766172998,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Stephen Quake as a director and beneficial owner of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLbTNglv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"gpt_icon":0},{"id":"2592618134","title":"Sector Update: Health Care Stocks Rise Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2592618134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592618134?lang=en_us&edition=fundamental","pubTime":"2025-12-19 04:55","pubTimestamp":1766091346,"startTime":"0","endTime":"0","summary":"Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF  each adding 0.3%.The iShares Biotechnology ETF  fell 0.8%.In corporate news, AbCellera Biologics  shares gained 5.2%. The company will receive $36 million upfront from Bruker  as part of a patent litigation settlement.Irenic Capital Management has built a stake of more than 3% in Integer  and is calling on the company to revamp its board and consider a sale as its shares trade at a discount, The Wall Street Journal reported. Integer shares climbed 5.6%.Eli Lilly  will reduce the prices of its diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada from Dec. 29, The Globe and Mail reported Thursday, citing a note to pharmacies Wednesday night. Eli Lilly shares rose 1.8%.Athira Pharma  shares surged about 66% after it disclosed Thursday that it agreed to acquire the rights for the development and commercialization of lasofoxifene ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1868836757.USD","BK4082","LU1035775433.USD","LU1267930730.SGD","LU0320765059.SGD","IE00BK4W5L77.USD","LU1551013342.USD","LU1559883803.SGD","LU2168563687.JPY","ITGR","LU1712237335.SGD","IE00B1BXHZ80.USD","LU2361045086.USD","LU1868836914.USD","IE0009355771.USD","LU0109394709.USD","LU2106854487.HKD","IE00B2B36J28.USD","LU0354030438.USD","LU1917777945.USD","LU1064131342.USD","LU0058720904.USD","LU0683600562.USD","IE00BJJMRY28.SGD","LU0787776722.HKD","SG9999017495.SGD","SG9999001176.SGD","LU2237443549.SGD","LU0823434740.USD","LU0889565916.HKD","LU1989771016.USD","LU0114720955.EUR","LU2237443465.HKD","LU0820561818.USD","LU2471134796.USD","SG9999015952.SGD","XLV","LU0456855351.SGD","LU2265009873.SGD","BK4535","LU1974910355.USD","LU2746668974.SGD","LU0203201768.USD","LU2360106947.USD","LU2750360641.GBP","SG9999013999.USD","LU0289739699.SGD","LU1127390331.HKD","LU0122379950.USD","SG9999015986.USD","LU0820561909.HKD","LU2023250504.SGD","LU2211815571.USD","LU0266013472.USD","LU2168564149.EUR","SG9999014898.SGD","LU2750360997.AUD","LU1023059063.AUD","SG9999015978.USD","LU2087625088.SGD","LU0320765992.SGD","LU2236285917.USD","LU2462157665.USD","BK4599","LU1061106388.HKD","SGXZ81514606.USD","LU0097036916.USD","ABCL","SG9999014914.USD","LU0471298694.HKD","LU0786609619.USD","LU2552382215.SGD","LU2471134523.USD","IE0002141913.USD","LU2108987350.USD","LU2491050154.USD","LU1814569148.SGD","SGXZ51526630.SGD","XBI","LU0640476718.USD","IE00BJJMRX11.SGD","LU1551013425.SGD","LU0238689110.USD","LU1868837300.USD","LU0385154629.USD","LU0256863902.USD","LU0094547139.USD","LU2089984988.USD","IE00BWXC8680.SGD","LU1169589451.USD","LU2361044865.SGD","LU2746668461.USD","LU1988902786.USD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","LU0256863811.USD","LU1291159041.SGD","LU1983299246.USD","LU2168564495.EUR","LU0316494557.USD","LU0566484027.USD","IE00B4R5TH58.HKD","LU2456880835.USD","LU0096364046.USD","LU0203202063.USD","BK4533","LU2471134879.HKD","LU2361044949.HKD","LU0029874061.USD","LU2237443978.SGD","LU1720051017.SGD","SG9999014880.SGD","LU2602419157.SGD","LU2468319806.SGD","LU0757428866.USD","BK4121","SG9999014906.USD","LU2491050071.SGD","LU2264538146.SGD","LU0354030511.USD","LU0417517546.SGD","LU2237443382.USD","IE00BK4W5M84.HKD","SG9999001176.USD","IE00BFSS7M15.SGD","LU0432979614.USD","LU1232071149.USD","LU2237443895.HKD","LU2112291526.USD","SGXZ31699556.SGD","LU1366192091.USD","IE00B775H168.HKD","LU0689472784.USD","LU2324357040.USD","LU2417539215.USD","LU2552382058.USD","IE0004445239.USD","IE00B1XK9C88.USD","LU0079474960.USD","IE00BKPKM429.USD","BK4581","LU0061475181.USD","LU0882574139.USD","LU2471134952.CNY","LU1548497426.USD","IE00BKDWB100.SGD","LU1804176565.USD","LU1057294990.SGD","LU1069344957.HKD","LU2357305700.SGD","LU0198837287.USD","LU0943347566.SGD","SGXZ57979304.SGD","LU1280957306.USD","LU0471298777.SGD","IE00B7KXQ091.USD","LU1868837136.USD","BK4585","LU2461242641.AUD","LU1323610961.USD","LU0109391861.USD","LU0466842654.USD","LU0672654240.SGD","IE00BJJMRZ35.SGD","BK4588","GB00BDT5M118.USD","LU1093756168.USD","LU2168564222.USD","LU1815336091.USD","IE00BFSS8Q28.SGD","LU0323591593.USD","LU2237443622.USD","BK4007","LU1093756325.SGD","IE00BN29S564.USD","LU2552382132.HKD","IE0004445015.USD","LU0234572021.USD","LU0823434583.USD","LU1720051108.HKD","LU2491049909.HKD","BK4516","IE00BJT1NW94.SGD","SG9999018865.SGD","LU1623119135.USD","LU0106261372.USD","SG9999018857.SGD","LU1169590202.USD","SG9999015945.SGD","LU0353189680.USD","LU0708995401.HKD","LU2168564065.EUR","LU1868836591.USD","SGXZ99366536.SGD","BK4534","LABU","LU0006306889.USD","LU2063271972.USD","ATHA","IE00B4JS1V06.HKD","LU0882574055.USD","IE0005OL40V9.USD","LU2237438978.USD","LU0128526141.USD","LU0823416689.USD","LU0353189763.USD"],"gpt_icon":1},{"id":"2592021989","title":"AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592021989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592021989?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:46","pubTimestamp":1766069199,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) said Thursday that Bruker (BRKR) will pay it $36 million up front as part of a settlement of patent litigation between the two companies.AbCellera said that as part of the s","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","LU0757428866.USD","ABCL","LU1815336091.USD","BRKR","BK4535"],"gpt_icon":0},{"id":"2592902607","title":"BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902607","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902607?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:42","pubTimestamp":1766068945,"startTime":"0","endTime":"0","summary":"BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent LitigationDec 18 (Reuters) - Abcellera Biologics Inc ABCL.O:ABCELLERA AND BRUKER REACH GLOBAL SETTLEMENT OF PATENT LITIGATIONABCELLERA BIOL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BRKR","BK4535","LU0757428866.USD","LU1815336091.USD","BK4121"],"gpt_icon":0},{"id":"2592901214","title":"Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2592901214","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592901214?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:05","pubTimestamp":1766066747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0QD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","BRKR","LU0757428866.USD","BK4535","ABCL","LU1815336091.USD"],"gpt_icon":0},{"id":"2592012949","title":"Abcellera and Bruker Reach Global Settlement of Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592012949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592012949?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:05","pubTimestamp":1766066747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BRKR","BK4535","ABCL","LU0757428866.USD","LU1815336091.USD","BK4121"],"gpt_icon":0},{"id":"2590365967","title":"AbCellera to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365967","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365967?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227918,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The live audio webcast of the presentation will be accessible through a link on AbCellera's Investor Relations website, with a replay available after the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4kBb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2589984264","title":"Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2589984264","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589984264?lang=en_us&edition=fundamental","pubTime":"2025-12-06 13:23","pubTimestamp":1764998616,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) just added another twist to its evolving story, as the board moved to replace long time auditor KPMG with Ernst and Young starting with the 2026 fiscal year.\nSee our latest analysis for AbCellera Biologics.\nThe auditor change lands amid a choppy stretch for the stock, with a roughly 24 percent 1 month share price return decline and a still negative 3 year total shareholder return, even though year to date and 1 year total shareholder returns have turned positive as...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/assessing-abcellera-biologics-abcl-valuation-as-it-shifts-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/assessing-abcellera-biologics-abcl-valuation-as-it-shifts-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4121","ABCL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.2897},{"period":"3month","weight":-0.1339},{"period":"6month","weight":-0.3075},{"period":"1year","weight":-0.0318},{"period":"ytd","weight":-0.1111}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.146022},{"month":3,"riseRate":0.2,"avgChangeRate":-0.064544},{"month":4,"riseRate":0.2,"avgChangeRate":-0.104908},{"month":5,"riseRate":0.6,"avgChangeRate":-0.032152},{"month":6,"riseRate":0.4,"avgChangeRate":0.119513},{"month":7,"riseRate":0.6,"avgChangeRate":0.046684},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}